CELSENSE, INC. — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): Urinary incontinence (UI) is one of the most prevalen
CELSENSE, INC. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $169,296
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PA13-088
- NAICS
- —
- Place of performance
- PA
- Period
- —
Description
DESCRIPTION (provided by applicant): Urinary incontinence (UI) is one of the most prevalent conditions, affecting approximately 40% of women in the United States and the Western world. Stress urinary incontinence (SUI) accounts for the largest portion of these women, and is found in women of all ages, including an estimated 30-40% of women above the age of 60. Despite the common surgical use of mid-urethral slings, this procedure is still associated with a disturbing level of complications. Regenerative medicine cellular therapy approaches have therefore garnered attention for treatment of SUI. In particular, the transplantation of adipose stem cells into or adjacent to the urethral sphincter muscle show promising results and appears to be a safe alternativeto traditional treatments. Efficacy of this therapy is likely dependent on both the delivery and retention of cells in the muscle but there are currently no means for assessing cellular persistence without an invasive biopsy. Celsense, Inc. focuses